Schering-Plough Corporation announced on March 5 that the FDA approved the intravenous (IV) formulation of temozolomide as an alternative to the already approved oral form of the drug, after the EU regulatory commission did likewise last month. Temozolomide is a chemotherapy agent for treatment of adults with newly diagnosed glioblastoma multiforme (GBM) combined with radiotherapy and then as a maintenance treatment, as well as for patients suffering from anaplastic astrocytoma (AA) that have experienced disease progression after taking chemotherapy.